Testing effectiveness (Phase 2)Study completedNCT03082677
What this trial is testing
Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies
Who this might be right for
Myeloid Hematologic MalignancyLymphoid Hematologic Malignancy
Memorial Sloan Kettering Cancer Center 20